Skip to Main Content

In an unusual move, the U.S. Embassy in the Netherlands is taking the Dutch government to task for policies that would purportedly undermine patent rights held by drug makers, drawing criticism from consumer advocates who argue such declarations place pharmaceutical industry profits over patients.

Late last month, the embassy issued a missive criticizing Dutch officials for plans to expand compulsory licensing and pharmaceutical compounding, which would “send a clear message” to companies that patents in the Netherlands “can be undermined or circumvented for short-term financial benefits.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!